Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Timothy J. Schroeder net worth and biography

Timothy Schroeder Biography and Net Worth

Director of INmune Bio

Mr. Schroeder has been a director since December, 2016 Mr. Schroeder has more than 35 years of clinical and academic industry experience in global drug and device development programs. He is CEO of CTI Clinical Trial and Consulting Services, a multi-national research firm with locations in North America, Europe, Latin America and Asia-Pacific. The firm has supported more than 100 drug and device approvals, and works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Mr. Schroeder was a faculty member of the University of Cincinnati College of Medicine. He previously served as Executive Vice President of Clinical Development at SangStat Medical Corporation, a firm he co-founded. Mr. Schroeder is a board member for more than a dozen corporate and non-profit organizations. He was named as and was recognized as .

What is Timothy J. Schroeder's net worth?: The estimated net worth of Timothy J. Schroeder is at least $711,739.42 as of July 12th, 2023. Mr. Schroeder owns 82,187 shares of INmune Bio stock worth more than $711,739 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Schroeder may own. Learn More about Timothy J. Schroeder's net worth.
How do I contact Timothy J. Schroeder?: The corporate mailing address for Mr. Schroeder and other INmune Bio executives is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. INmune Bio can also be reached via phone at (858) 964-3720 and via email at [email protected]. Learn More on Timothy J. Schroeder's contact information.
Has Timothy J. Schroeder been buying or selling shares of INmune Bio?: Timothy J. Schroeder has not been actively trading shares of INmune Bio during the last quarter. Most recently, Timothy J. Schroeder sold 10,000 shares of the business's stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $11.01, for a transaction totalling $110,100.00. Following the completion of the sale, the director now directly owns 82,187 shares of the company's stock, valued at $904,878.87. Learn More on Timothy J. Schroeder's trading history.
Who are INmune Bio's active insiders?: INmune Bio's insider roster includes Mark Lowdell (Insider), David Moss (CFO), Timothy Schroeder (Director), and Raymond Tesi (CEO). Learn More on INmune Bio's active insiders.
Are insiders buying or selling shares of INmune Bio?: During the last twelve months, INmune Bio insiders bought shares 1 times. They purchased a total of 7,000 shares worth more than $48,650.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 10,000 shares worth more than $110,100.00. The most recent insider tranaction occured on November, 10th when Director Scott Juda bought 7,000 shares worth more than $48,650.00. Insiders at INmune Bio own 36.1% of the company. Learn More about insider trades at INmune Bio.
Information on this page was last updated on 11/10/2023.

Timothy J. Schroeder Insider Trading History at INmune Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/12/2023	Sell	10,000	$11.01	$110,100.00	82,187
7/13/2021	Sell	14,480	$27.63	$400,082.40
7/9/2021	Sell	30,000	$23.20	$696,000.00
6/14/2021	Sell	10,000	$19.02	$190,200.00

Timothy J. Schroeder Buying and Selling Activity at INmune Bio

INmune Bio Company Overview

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Today's Range

Now: $8.37

$8.30

$8.99

50 Day Range

MA: $11.68

$8.43

$14.01

2 Week Range

Now: $8.37

$6.50

$14.74

Volume

69,216 shs

Average Volume

87,659 shs

Market Capitalization

$152.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99